Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Trial Profile

Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 10 Feb 2018 Results of analyses of health-related quality of life (HRQoL) decline presented at the 2018 Genitourinary Cancers Symposium.
    • 10 Feb 2018 Results of analysis comparing enzalutamide with bicalutamide using the number needed to treat (NNT) to achieve one additional pt with m0CRPC, with either a progression-free survival event, radiographic PFS, or free of prostate-specific antigen progression at 1 year and 2 years presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 Results of post hoc analysis evaluating the hepatic effects of enzalutamide versus comparators in controlled castration-resistant prostate cancer trials (NCT0121299; NCT00974311; NCT01664923; NCT01288911) presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top